Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (6208)	2/18/1999 12:06:00 AM
From: Bruce Rosen	Read Replies (2) \| Respond to of 7041

It should be remembered that Schering is completely in charge of the sales and marketing of Vasomax. I don't believe that their reason for getting Mexican approval was to begin earning profits on Vasomax immediately. They know that the U.S. and to a lesser extent, Europe and Japan are far more lucrative markets. I have heard that Schering has hired a major ad agency to prepare a campaign for Vasomax. Anyone ever hear of Claritin? That's a Schering product. The promotion for that was the best I've ever seen for a drug. I believe that S-P will try very hard to promote Vasomax. Nothing of the kind was done in Mexico. In fact, I haven't heard even one reliable report of any advertising or other attempt to reach the Mexican market. Schering probably realizes that Mexico should be a small part of the overall marketing program that will begin in earnest upon anticipated U.S. approval. So why even bother with Mexican approval and "filling the pipeline?" Schering knows that the best chance to establish a niche for Vasomax is to provide data that Vasomax has less side effects and negative interactions than Viagra. While the data so far has indicated that is so, the more proof, the better. I suspect that Schering is working with whichever physicians are prescribing Vasomax and carefully gathering data.